CooperVision launches myopia management programme
The Brilliant Futures programme is now available in the UK, featuring tools to equip and support practices in myopia management
The company explained that the programme seeks to “introduce a new standard of care for children with myopia,” providing inclusive practice and child and parent support, with features for practices including communication tools and a new support system.
As part of the new programme, CooperVision has created a professional accreditation programme which aims to equip eye care professionals to understand and build a myopia management practice. The programme is delivered through CooperVision’s online learning academy ahead of gaining access to Brilliant Futures.
The new programme also features in-practice tools to help practitioners identify the children who are most at-risk of developing myopia. These include communication tools to support the introduction and commitment to intervention.
In the future, the programme will also feature a messaging portal to offer user support. Currently in development, the text-based system will link patients to practitioners in order to gauge their experience and identify support needs.
Describing the reasons behind the development of the Brilliant Futures programme, Mark Halling, myopia programme manager for CooperVision, highlighted: “The prevalence of childhood myopia in the UK has more than doubled over the past 50 years.
“This year’s lockdown measures, where many children have spent less time outdoors and more time learning via screen-based platforms, may influence the development of myopia. It is vital to manage this progression early, and with urgency, to help protect future eye health,” Mr Halling continued.
The new programme will help eye care practitioners, and parents, to slow myopic progression, Mr Halling added.
Commenting on the new programme, Indie Grewal, optometrist and president of the British Contact Lens Association (BCLA), said: “This innovative approach has the potential to revolutionise clinical outcomes and can allow us to change the trajectory of childhood myopia in practice. We now have an opportunity to tackle myopia head-on and ultimately help young patients see well into the future.”
The programme is built around CooperVision’s MiSight 1 day contact lenses with ActivControl Technology.
The company suggests the lens has been clinically proven to slow the progression of myopia in children as young as eight, compared to a single vision 1 day lens, over a three-year period.
Last year, CooperVision published three-year peer-reviewed results from its research into the effectiveness of the MiSight lens, which indicated that use of MiSight 1 Day was shown to slow myopia progression by 59% on average (measured by mean cycloplegic spherical equivalent) and 52% on average when measured by mean axial elongation of the eye.
The trial has continued, with the original control group refitted with MiSight 1 day, which the company suggested has shown “highly encouraging results” for the fourth and fifth years of the study.
The company’s research into the effectiveness of MiSight has been the longest continuous soft contact lens study for myopia management.